Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.00.

Several research analysts have weighed in on ZURA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a research note on Monday, July 6th. Guggenheim lifted their target price on shares of Zura Bio from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. William Blair started coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Zura Bio from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Finally, Wedbush upped their price target on shares of Zura Bio from $15.00 to $22.00 and gave the stock an “outperform” rating in a research note on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ZURA. Bank of America Corp DE lifted its holdings in shares of Zura Bio by 3,007.7% during the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after buying an additional 132,130 shares during the last quarter. Stempoint Capital LP bought a new position in Zura Bio during the first quarter valued at approximately $4,483,000. ADAR1 Capital Management LLC lifted its stake in Zura Bio by 12.2% in the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after acquiring an additional 68,338 shares during the last quarter. EcoR1 Capital LLC acquired a new stake in Zura Bio in the first quarter valued at approximately $7,019,000. Finally, Commodore Capital LP bought a new stake in Zura Bio in the first quarter worth approximately $19,338,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Price Performance

NASDAQ:ZURA opened at $5.57 on Monday. The stock has a market cap of $528.48 million, a PE ratio of -4.93 and a beta of -0.02. Zura Bio has a fifty-two week low of $1.64 and a fifty-two week high of $7.44. The stock’s 50-day moving average is $4.99 and its two-hundred day moving average is $5.39.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Zura Bio will post -0.81 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.